CoChat

The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.

Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19

Open access
Altay, Ozlem, Arif, Muhammad, Li, Xiangyu, Yang, Hong, Aydın, Mehtap, Alkurt, Gizem, Kim, Woonghee, Akyol, Dogukan, Zhang, Cheng, Dinler‐Doganay, Gizem, Turkez, Hasan, Shoaie, Saeed, Nielsen, Jens, Borén, Jan, Olmuscelik, Oktay, Doganay, Levent, Uhlén, Mathias, Mardinoglu, Adil · 2021 · Advanced Science

Published version of a preprint

Abstract

COVID‐19 is associated with mitochondrial dysfunction and metabolic abnormalities, including the deficiencies in nicotinamide adenine dinucleotide (NAD + ) and glutathione metabolism. Here it is investigated if administration of a mixture of combined metabolic activators (CMAs) consisting of glutathione and NAD+ precursors can restore metabolic function and thus aid the recovery of COVID‐19 patients. CMAs include l ‐serine, N ‐acetyl‐ l ‐cysteine, nicotinamide riboside, and l ‐carnitine tartrate, salt form of l ‐carnitine. Placebo‐controlled, open‐label phase 2 study and double‐blinded phase 3 clinical trials are conducted to investigate the time of symptom‐free recovery on ambulatory patients using CMAs. The results of both studies show that the time to complete recovery is significantly shorter in the CMA group (6.6 vs 9.3 d) in phase 2 and (5.7 vs 9.2 d) in phase 3 trials compared to placebo group. A comprehensive analysis of the plasma metabolome and proteome reveals major metabolic changes. Plasma levels of proteins and metabolites associated with inflammation and antioxidant metabolism are significantly improved in patients treated with CMAs as compared to placebo. The results show that treating patients infected with COVID‐19 with CMAs lead to a more rapid symptom‐free recovery, suggesting a role for such a therapeutic regime in the treatment of infections leading to respiratory problems.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/advs.202101222

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The effect of CMA on the symptoms of COVID‐19 patients in phase‐2 clinical trial. A) The effect of the CMA in 93 COVID‐19 patients is tested in a randomized, controlled, open‐label, placebo‐controlled phase 2 clinical study. Study design for testing the effect of CMA is presented. B) Based on Kaplan–Meier analysis, it is shown that CMA accelerates the recovery of the COVID‐19 patients. Number of patients reporting COVID‐19 symptoms are reported in the Table S2 (Supporting Information). C) Multivariate Cox regression analysis of CMA treatment in phase‐2 clinical trial.
Figure 1 The effect of CMA on the symptoms of COVID‐19 patients in phase‐2 clinical trial. A) The effect of the CMA in 93 COVID‐19 patients is tested in a randomized, controlled, open‐label, placebo‐controlled phase 2 clinical study. Study design for testing the effect of CMA is presented. B) Based on Kaplan–Meier analysis, it is shown that CMA accelerates the recovery of the COVID‐19 patients. Number of patients reporting COVID‐19 symptoms are reported in the Table S2 (Supporting Information). C) Multivariate Cox regression analysis of CMA treatment in phase‐2 clinical trial.CC BY · PubMed Central
Figure 2 The effect of CMA on the symptoms of COVID‐19 patients in phase‐3 clinical trial. A) The effect of the CMA in 304 COVID‐19 patients is tested in a randomized, controlled, double‐blinded, placebo‐controlled phase 3 clinical study. Study design for testing the effect of CMA is presented. B) Based on Kaplan–Meier analysis, it is shown that CMA accelerates the recovery of the COVID‐19 patients. Number of patients reporting COVID‐19 symptoms are reported in the Table S2 (Supporting Information). C) Multivariate Cox regression analysis of CMA treatment in phase‐3 clinical trial.
Figure 2 The effect of CMA on the symptoms of COVID‐19 patients in phase‐3 clinical trial. A) The effect of the CMA in 304 COVID‐19 patients is tested in a randomized, controlled, double‐blinded, placebo‐controlled phase 3 clinical study. Study design for testing the effect of CMA is presented. B) Based on Kaplan–Meier analysis, it is shown that CMA accelerates the recovery of the COVID‐19 patients. Number of patients reporting COVID‐19 symptoms are reported in the Table S2 (Supporting Information). C) Multivariate Cox regression analysis of CMA treatment in phase‐3 clinical trial.CC BY · PubMed Central
Figure 3 The effect of the CMA on clinical variables. A) Heatmap shows log2FC based alterations of the clinical variables, which are compared before and after the administration of CMA in both active and placebo groups. Asterisks indicate statistical significance based on Student's t‐test. P value <0.05. The level of clinical variables including B) ALT, C) LDH, D) creatinine, and E) glucose is presented in the CMA and placebo groups in all 397 patients involved in Phase 2 and Phase 3 clinical trials. These clinical parameters are significantly improved due to the administration of CMA after 14 d. The decrease in the recovery of the patients has been supported by the improvement in clinical variables and the metabolic health status of the patients.
Figure 3 The effect of the CMA on clinical variables. A) Heatmap shows log2FC based alterations of the clinical variables, which are compared before and after the administration of CMA in both active and placebo groups. Asterisks indicate statistical significance based on Student's t‐test. P value <0.05. The level of clinical variables including B) ALT, C) LDH, D) creatinine, and E) glucose is presented in the CMA and placebo groups in all 397 patients involved in Phase 2 and Phase 3 clinical trials. These clinical parameters are significantly improved due to the administration of CMA after 14 d. The decrease in the recovery of the patients has been supported by the improvement in clinical variables and the metabolic health status of the patients.CC BY · PubMed Central
Figure 4 CMA alters the global metabolism of the patients. A) The plasma level of individual metabolic activators including serine, carnitine, nicotinamide riboside, and cysteine as well as B) their association with the 10 most significantly correlated plasma metabolites are presented using the plasma samples obtained from 93 patients in Phase 2 clinical trial. Asterisks indicate statistical significance based on Spearman correlation analysis. FDR value <0.01.
Figure 4 CMA alters the global metabolism of the patients. A) The plasma level of individual metabolic activators including serine, carnitine, nicotinamide riboside, and cysteine as well as B) their association with the 10 most significantly correlated plasma metabolites are presented using the plasma samples obtained from 93 patients in Phase 2 clinical trial. Asterisks indicate statistical significance based on Spearman correlation analysis. FDR value <0.01.CC BY · PubMed Central
Figure 5 CMA affects the plasma level of inflammation related proteins. Association between inflammation related proteins that are significantly different between the CMA and placebo groups on Days 0 and Day 14 using the plasma samples obtained from 93 patients in Phase 2 clinical trial. A) Heatmap shows log2FC based alterations and clustering between significant proteins on Day 14 versus Day 0 in the CMA and placebo groups. Asterisks indicate statistical significance based on paired Student's t test. FDR value: < 0.01. B) Heatmap shows the correlation and clustering between the plasma level all inflammation related proteins and plasma levels of the individual constituents of CMA (including serine, carnitine, nicotinamide riboside, and cysteine). Asterisks indicate statistical significance based on Spearman correlation analysis. p value: < 0.05. Log2FC: log2(fold change).
Figure 5 CMA affects the plasma level of inflammation related proteins. Association between inflammation related proteins that are significantly different between the CMA and placebo groups on Days 0 and Day 14 using the plasma samples obtained from 93 patients in Phase 2 clinical trial. A) Heatmap shows log2FC based alterations and clustering between significant proteins on Day 14 versus Day 0 in the CMA and placebo groups. Asterisks indicate statistical significance based on paired Student's t test. FDR value: < 0.01. B) Heatmap shows the correlation and clustering between the plasma level all inflammation related proteins and plasma levels of the individual constituents of CMA (including serine, carnitine, nicotinamide riboside, and cysteine). Asterisks indicate statistical significance based on Spearman correlation analysis. p value: < 0.05. Log2FC: log2(fold change).CC BY · PubMed Central
Figure 6 CMA affects the plasma level of amino acids and improves metabolic health. Plasma level of amino acids that are significantly different on Days 14 versus Day 0 in the CMA and placebo groups using the plasma samples obtained from 93 patients in Phase 2 clinical trial. A) Venn‐diagram representing the number of identified amino acids that are significantly different on Days 14 versus Day 0 in the CMA and placebo groups. The intersection represents amino acids that were altered in both groups. Statistical significance based on paired Student's t test. FDR value: < 0.001. Association between the plasma level of significantly different amino acids B) in both groups (n = 25); C) only in CMA group (n = 70), and D) only in placebo group (n = 6) on Day 14 versus Day 0. Heatmap shows log2FC based alterations in the amino acids and asterisks indicate statistical significance based on paired Student's t test. FDR value: < 0.001. Log2FC, log2(fold change).
Figure 6 CMA affects the plasma level of amino acids and improves metabolic health. Plasma level of amino acids that are significantly different on Days 14 versus Day 0 in the CMA and placebo groups using the plasma samples obtained from 93 patients in Phase 2 clinical trial. A) Venn‐diagram representing the number of identified amino acids that are significantly different on Days 14 versus Day 0 in the CMA and placebo groups. The intersection represents amino acids that were altered in both groups. Statistical significance based on paired Student's t test. FDR value: < 0.001. Association between the plasma level of significantly different amino acids B) in both groups (n = 25); C) only in CMA group (n = 70), and D) only in placebo group (n = 6) on Day 14 versus Day 0. Heatmap shows log2FC based alterations in the amino acids and asterisks indicate statistical significance based on paired Student's t test. FDR value: < 0.001. Log2FC, log2(fold change).CC BY · PubMed Central
Figure 7 Integrated network analysis for revealing the effect of CMA on patients. Association between the plasma level of clinical variables including ALT, AST, LDH, TGs, and hemoglobin with plasma level of all inflammation related proteins. Heatmap shows log2FC based alterations and clustering between the plasma level of clinical variables including ALT, AST, LDH, TG, and hemoglobin with plasma level of A) all metabolites and B) all inflammation related proteins. Asterisks indicate statistical significance based on paired Student's t test. p value: < 0.05. Log2FC, log2(fold change); AST, Aspartate aminotransferase; ALT, Alanine transaminase; LDH, Lactate dehydrogenase; TGs, Triglycerides. C) Neighbors of the metabolic activators including serine, carnitine, nicotinamide riboside, and cysteine based on the multiomics network analysis. Only analytes that are significantly altered in CMA Day 14 versus Day 0 are highlighted. Full networks can be found in iNetModels (http://inetmodels.com).
Figure 7 Integrated network analysis for revealing the effect of CMA on patients. Association between the plasma level of clinical variables including ALT, AST, LDH, TGs, and hemoglobin with plasma level of all inflammation related proteins. Heatmap shows log2FC based alterations and clustering between the plasma level of clinical variables including ALT, AST, LDH, TG, and hemoglobin with plasma level of A) all metabolites and B) all inflammation related proteins. Asterisks indicate statistical significance based on paired Student's t test. p value: < 0.05. Log2FC, log2(fold change); AST, Aspartate aminotransferase; ALT, Alanine transaminase; LDH, Lactate dehydrogenase; TGs, Triglycerides. C) Neighbors of the metabolic activators including serine, carnitine, nicotinamide riboside, and cysteine based on the multiomics network analysis. Only analytes that are significantly altered in CMA Day 14 versus Day 0 are highlighted. Full networks can be found in iNetModels (http://inetmodels.com).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 3

  1. Thomas T., 2020, JCI Insight, 5
  2. Hundt M. A., 2020, Hepatology
  3. 10.1038/pr.2013.71 · DOI

Cited by

See all 99

Metadata

Authors
Altay, O., Arif, M., Li, X., Yang, H., Aydın, M., Alkurt, G., Kim, W., Akyol, D., Zhang, C., Dinler‐Doganay, G., Turkez, H., Shoaie, S., Nielsen, J., Borén, J., Olmuscelik, O., Doganay, L., Uhlén, M., & Mardinoglu, A.
Affiliations
  • Science for Life Laboratory KTH—Royal Institute of Technology Stockholm SE‐100 44 Sweden
  • Science for Life Laboratory (SE)
  • Ümraniye Eğitim ve Araştırma Hastanesi (TR)
  • Department of Molecular Biology and Genetics Istanbul Technical University Istanbul 34469 Turkey
  • Department of Medical Biology Faculty of Medicine Atatürk University Erzurum 25240 Turkey
  • King's College London (GB)
  • Chalmers University of Technology (SE)
  • Sahlgrenska University Hospital (SE)
  • Department of Internal Medicine Istanbul Medipol University Bagcılar Istanbul 34214 Turkey
  • Department of Gastroenterology Umraniye Training and Research Hospital University of Health Sciences Istanbul 34766 Turkey
Venue
Advanced Science
Publisher
Wiley
Published
2021-06-28
Volume
8
Issue
17
Pages
e2101222-e2101222
ISSN
2198-3844 (ISSN-L)
OpenAlex
W3174268490
Cited by
88
References
55
Citations by year
2026: 4 · 2025: 9 · 2024: 15 · 2023: 23 · 2022: 23 · 2021: 13
FWCI
6.09
Type
journal article
Language
en
Open access
Locations
  • Advanced Science (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Chalmers Research (Chalmers University of Technology) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Research Portal (King's College London) (submittedVersion, other-oa)
  • Istanbul Technical University Academic Open Archive (Istanbul Technical University) (submittedVersion)
Funders
Knut och Alice Wallenbergs Stiftelse (20120)
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords
COVID-19 pandemic, glutathione, NAD+ precursors, N-acetylcysteine, nicotinamide riboside, L-serine, plasma metabolome, plasma proteome, inflammation, antioxidant metabolism, metabolic therapy
MeSH terms
COVID-19, Adult, Aged, Antioxidants, Double-Blind Method, Female, Humans, Inflammation, Male, Middle Aged, Proteins, Proteome, Metabolome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19. https://app.cochat.ai/papers/10.1002/advs.202101222
The paper
Altay, O., Arif, M., Li, X., Yang, H., Aydın, M., Alkurt, G., Kim, W., Akyol, D., Zhang, C., Dinler‐Doganay, G., Turkez, H., Shoaie, S., Nielsen, J., Borén, J., Olmuscelik, O., Doganay, L., Uhlén, M., & Mardinoglu, A. (2021). Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19. Advanced Science. https://doi.org/10.1002/advs.202101222

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.